Alva - Your AI Investing Agent

Dr J Rould

Full-Time Tech Investor, Quantum/Cybersecurity, Philosophy Background

7 May, 19:21Latest

The valuation gap between Strata Critical Medical and TransMedics should close as Strata scales profitably while TransMedics burns cash. Strata's margins improve with scale, and its kidney logistics market is largely untapped, so new competitors would face its first-mover advantage. TransMedics has the stronger technical moat and may build superior warm-perfusion kidney devices, but trials are a science project until they deliver profits. Both could succeed, and might even cooperate. x.com x.com x.com x.com x.com x.com

SRTA

TMDX

6 May, 22:18

Strata Critical Medical should keep closing its valuation gap with TransMedics because it grows on lighter costs while TransMedics' margins shrink. Strata handles logistics for simple organs like kidneys, most transplants, which can sit in a cooler, while TransMedics builds costly mini-ICU systems for hearts and lungs. Earnings confirmed it: both grew, but TransMedics' margins were crushed as it scales while Strata's expanded. Strata's market cap went from a tenth of TransMedics' to a sixth. x.com x.com

SRTA

TMDX

The Inflection Economy

Portfolio Managers at Logos LP

22 Jun

SRTA

Strata Critical Medical is a reclassification story, having turned from Blade's helicopters and eVTOL optionality into a pure-play organ transplant logistics and clinical services platform. Everyone knows the TransMedics story, but Strata is the more interesting setup from here. x.com

The Few Bets That Matter

Concentrated Equity Investor, AI Infrastructure

5 May

TMDX

TransMedics now looks weak, and weak names are not worth touching regardless of how cheap they look. The market is selling on falling operating margins; rising costs come from R&D and clinical trials, which is healthy, but there is more to it than margins. TransMedics is not passing fuel costs fully to customers, covering only part with a flat fee, and it is now offering cold-storage transplants, shifting from running both trial arms itself to offering the service. x.com x.com x.com x.com x.com

Ashton Invests

Long-Term Equity Investor, Fundamental Stock Research

20 Oct

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com x.com x.com x.com x.com x.com x.com x.com

Monis

Equities Trader, Oversold Reversals & Earnings Plays

13 May

TMDX

TransMedics capital is better deployed elsewhere for now, with no near-term catalyst and weak price action. A post the author replies to notes that FY26 guidance includes revenue from heart trials, so without starting those trials soon the company can't meet it, and the market is arguably pricing in a miss. A re-evaluation would come once price action improves. x.com x.com

taobanker

App Builder

9 Jul

TMDX

TransMedics' best trade is likely over: in biotech, by the time competition starts being discussed, most of the gain has been made. Another investor notes its technology is great but very expensive, with many working to replace it. x.com

TacticzHazel

Energy-Market Analyst, Long-Term Fundamental Investing

13 Jul

TMDX

TransMedics' long-term story stands despite a roughly 60% stock drop, because its organ transplant model is hard to replicate. It sells the machines and also handles retrieval and transport with its own aviation fleet and clinical teams. Margins are compressed by deliberate heavy investment, alongside regulatory issues and a lingering short report. About three-quarters of the TAM remains in the US, Europe is opening through Italy and PAD Aviation, and kidney transplants could double the TAM. … Show more

Ask Alva about this thesis

Ask Alva about this thesis